With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

On Saturday, GSK announced full results from the ANCHOR-1 and ANCHOR-2 phase 3 trials of depemokimab versus placebo (both with the standard of care [SOC]) in adults with CRSwNP. ANCHOR-1 (N=271 ...

GSK plc GSK announced that the FDA has approved ... Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type ...

According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab as ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

Daniel J. Jackson In the previous phase 3 SWIFT-1/2 studies, two doses of depemokimab (GSK) administered at week 0 and 26 in addition to standard of care reduced asthma exacerbations by ...

According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab ...